Asset profile

Fulvestrant · Faslodex

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — HR+/HER2- Metastatic Breast Cancer

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(86 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (12)

August 2026 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-08-23 · NCT05262400 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (1)

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-09-23 · NCT04557449 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (3)

Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2026-10 · NCT06929325 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-10-30 · NCT04851613 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-10-31 · NCT06635447 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (1)

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-11-13 · NCT05646862 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (6)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2026-12 · NCT06202261 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12 · NCT04115306 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12 · NCT02738866 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2026-12-01 · NCT05305924 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12-31 · NCT04553133 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12-31 · NCT05226871 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (33)

January 2027 (3)

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-01-28 · NCT05038735 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-01-29 · NCT04544189 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-01-31 · NCT02476786 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (2)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-02-01 · NCT06447623 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-02-26 · NCT04524000 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (2)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-03-01 · NCT06179303 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-03-15 · NCT00585507 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (5)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-04 · NCT07426822 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2027-04-01 · NCT05986071 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8 …Active not recruiting

Est. primary completion 2027-04-01 · NCT05319873 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-04-01 · NCT01953588 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (1)

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-05-05 · NCT06428396 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (4)

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-06 · NCT04920708 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-06 · NCT07117630 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-06-30 · NCT06993844 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-06-30 · NCT07498478 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (2)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-07 · NCT05735080 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-07-22 · NCT07062965 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (2)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-09 · NCT07180160 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-09-01 · NCT04985266 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (2)

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-10-08 · NCT05090358 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-10-30 · NCT06612814 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (4)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-11 · NCT06110793 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-11-01 · NCT04862663 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Brest CancerNot yet recruiting

Est. primary completion 2027-11-20 · NCT07333937 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-11-25 · NCT07330544 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (6)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-12 · NCT06555068 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-12 · NCT07227233 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-12-31 · NCT05608252 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-12-31 · NCT05601440 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-12-31 · NCT04567420 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-12-31 · NCT06764186 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (24)

January 2028 (2)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-01 · NCT07235618 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2028 (2)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-02 · NCT05573126 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-02-28 · NCT07287917 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-03-31 · NCT06788197 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2028 (1)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-04-30 · NCT06982521 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-06-30 · NCT07666555 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2028 (1)

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2028-07 · NCT05625087 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (3)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-08 · NCT06998407 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-08-15 · NCT05467891 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-08-31 · NCT07393321 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (2)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-09-25 · NCT06726148 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-09-28 · NCT07619066 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (2)

Phase 1/2Advanced Solid TumorsNot yet recruiting

Est. primary completion 2028-10-28 · NCT07767474 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-10-31 · NCT07368998 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2028 (2)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-11-02 · NCT07235176 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Metastatic (Stage IV) MelanomaNot yet recruiting

Est. primary completion 2028-11-18 · NCT07340619 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (7)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-12 · NCT07389733 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-12 · NCT07618390 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-12-14 · NCT04646759 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-12-19 · NCT07405801 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-12-30 · NCT07109726 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-12-31 · NCT05524584 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-12-31 · NCT05816655 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (7)

March 2029 (1)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-03-31 · NCT06757634 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2029 (3)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-05 · NCT07558733 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-05 · NCT07174336 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-05-31 · NCT07207070 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2029 (1)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2029-06-15 · NCT07748208 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2029 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-07-13 · NCT04606446 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (1)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (6)

July 2030 (2)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-07-01 · NCT05564377 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2030 (1)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2030-08-31 · NCT07716046 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2030 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-10 · NCT05933395 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (1)

Phase 2HER2-positive Breast CancerNot yet recruiting

Est. primary completion 2030-12-30 · NCT07179939 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (4)

May 2031 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2031-05-09 · NCT07288359 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2031 (3)

Phase 2Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer …Recruiting

Est. primary completion 2031-06-02 · NCT07340541 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2031-06-27 · NCT07679269 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2031-06-30 · NCT06849947 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.